Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity

Summary

In women diagnosed as having category I primary obstetric antiphospholipid syndrome, clinical characteristics and the risk of subsequent thromboembolic events and further unsuccessful pregnancy has not been clearly documented. Women with unexplained obstetric complications and no definite autoimmune systemic diseases were tested for lupus anticoagulant (LA), IgG/ IgM anticardiolipin (aCL) and IgG/IgM anti-human β2-Glycoprotein I (aβ2GPI) antibodies and diagnosed as having primary antiphospholipid syndrome (APS) in classification category I on the basis of more than one laboratory criteria present in any combination. Characteristics at the time of diagnosis and risk factors for subsequent clinical events during a mean follow-up of 6.3 years were evaluated. Fifty-three of 600 women studied were found to fulfil obstetric criteria and had more than one positive laboratory test at the time of diagnosis. All the women were a CL and aβ2GPI positive, and 16 were also LA positive. This latter group (triple positivity) had distinct features and had more frequently experienced previous thromboembolism (OR= 122.5, 95% CI 16–957, p<0.001).They also had an increased rate of late pregnancy loss (OR=16.2, 95%CI 0.9–292, p=0.01), and a higher IgG aβ2GPI titer at diagnosis (median, 25^th and 75^th percentile were 118, 37–962, vs. 23, 18–32, respectively, p<0.0001). During follow-up, the rate of thromboembolic events was significantly higher in the group of women with triple positivity and/ or previous thromboembolism (OR=57.5, 95% CI 2.7–1160, p=0.0004) which were the only independent predictors of TE in the multivariate model. Recurrent pregnancy loss took place in seven out of 47 women who had a new pregnancy. Triple positivity and/or previous thromboembolism were again the only independent markers (OR=34.4, 95% CI 3.5–335.1, p=0.003) of an unsuccessful new pregnancy. In conclusion, in primary APS with pregnancy morbidity in classification category I, quite different groups of patients may be identified on the basis of laboratory tests. Triple positivity and/or a history of thromboembolism predict new TE events and new unsuccessful pregnancies.

Keywords

Antiphospholipid antibodies - thrombophilia - pregnancy

• References

• 1 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-11.
• 2 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 04: 295-306.
• 3 Detkova D, Gil-Aguado A, Lavilla P. et al. Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?. Lupus 1999; 08: 430-8.
• 4 Lee EY, Lee CK, Lee TH. et al. Does the antibeta2-glycoprotein I antibody provide additional information in patients with thrombosis?. Thromb Res 2003; 111: 29-32.
• 5 Pengo V, Biasiolo A, Pegoraro C. et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-52.
• 6 Sailer T, Zoghlami C, Kurz C. et al. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost 2006; 95: 796-801.
• 7 Zoghlami-Rintelen C, Vormittag R, Sailer T. et al. The presence of IgG antibodies against beta2-glycoproteinI predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005; 03: 1160-5.
• 8 Khamashta MA. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmunity 2000; 15: 249-53.
• 9 Erkan D, Merrill JT, Yazici Y. et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001; 44: 1466-7.
• 10 Vitali C, Bombardieri VC, Moutsopoulos HM. et al. Preliminary criteria for the classification of Sjogren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36: 340-7.
• 11 Tan EM, Cohen AS, Fries JF. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
• 12 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
• 13 Arnett FC, Edworthy SM, Bloch DA. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 03: 315-24.
• 14 Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
• 15 Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-7. 403-7.
• 16 Pengo V, Biasiolo A, Pegoraro C. et al. A two-step coagulation test to identify anti-beta2-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 02: 702-7.
• 17 Brandt JT, Triplett DA, Alvin B. et al. Criteria for the diagnosis of lupus anticoagulant. Thromb Haemost 1995; 74: 1185-90.
• 18 Pengo V, Biasiolo A, Rampazzo P. et al. dRVVT is more sensitive than KCT or TTI for detecting Lupus Anticoagulant activity of anti-β2-Glycoprotein-I autoantibodies. Thromb Haemost 1999; 81: 256-8.
• 19 Biasiolo A, Pengo V. Antiphospholipid antibodies are not present in the membrane of gel-filtered platelets of patients with IgG anticardiolipin antibodies, lupus anticoagulant and thrombosis. Blood Coagul Fibrinolysis 1993; 04: 425-8.
• 20 Tincani A, Allegri F, Balestrieri G. et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553-8.
• 21 Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-Glycoprotein-I is bound to a suitable surface. Thromb Haemost 1995; 73: 29-34.
• 22 Reber G, Tincani A, Sanmarco M. et al. Proposal for the measurements of anti-β2-Glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 02: 1860-2.
• 23 Allison PD. Logistic regression using the SAS system. Theory and Application. SAS institute inc. Cary, NC, USA 1999; chapter 3.4, 39-48.
• 24 Ruffatti A, Orsini A, DiLenardo L. et al. A prospective study of fifty-three consecutive calcium heparin treated pregnancies in patients with antiphospholipidrelated fetal loss. Clin Exp Rheumatol 1997; 15: 499-505.
• 25 Ruffatti A, Favaro M, Tonello M. et al. Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome. Lupus 2005; 14: 120-8.
• 26 Garcia CO, Kanbour-Shakir A, Tang H. et al. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI. Am J Reprod Immunol 1997; 37: 118-24.
• 27 Branch DW, Scott JR, Kochenour NK. et al. Obstetric complications associated with the Lupus Anticoagulant. N Engl J Med 1985; 313: 1322-6.
• 28 Branch DW. Antiphospholipid antibodies and foetal compromise. Thromb Res 2004; 114: 415-8.
• 29 Finazzi G, Brancaccio V, Moia M. et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-6.
• 30 Tincani A, Branch W, Levy RA. et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003; 12: 524-9.